American International Group Inc. Reduces Stake in Merck & Co., Inc. (NYSE:MRK)

American International Group Inc. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.9% during the fourth quarter, Holdings Channel reports. The firm owned 655,769 shares of the company’s stock after selling 12,503 shares during the quarter. American International Group Inc.’s holdings in Merck & Co., Inc. were worth $71,492,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Cross Staff Investments Inc lifted its position in shares of Merck & Co., Inc. by 3.5% in the fourth quarter. Cross Staff Investments Inc now owns 6,710 shares of the company’s stock valued at $732,000 after acquiring an additional 225 shares in the last quarter. Kennedy Investment Group boosted its stake in shares of Merck & Co., Inc. by 16.0% during the 4th quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock worth $280,000 after purchasing an additional 354 shares during the last quarter. Schear Investment Advisers LLC grew its holdings in shares of Merck & Co., Inc. by 16.0% during the fourth quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock worth $352,000 after buying an additional 445 shares in the last quarter. Knuff & Co LLC raised its position in shares of Merck & Co., Inc. by 1.7% in the fourth quarter. Knuff & Co LLC now owns 12,270 shares of the company’s stock valued at $1,338,000 after buying an additional 200 shares during the last quarter. Finally, Constitution Capital LLC lifted its stake in shares of Merck & Co., Inc. by 5.9% during the fourth quarter. Constitution Capital LLC now owns 3,600 shares of the company’s stock valued at $392,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.8 %

Merck & Co., Inc. stock traded up $1.10 during trading on Thursday, reaching $130.55. 8,088,511 shares of the company’s stock were exchanged, compared to its average volume of 8,097,944. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10. The firm has a market cap of $330.66 billion, a price-to-earnings ratio of 145.06, a PEG ratio of 1.66 and a beta of 0.39. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The company’s 50-day moving average is $128.53 and its two-hundred day moving average is $121.14.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 earnings per share. On average, analysts predict that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date of this dividend is Monday, June 17th. Merck & Co., Inc.’s payout ratio is 342.22%.

Analyst Ratings Changes

Several research firms have commented on MRK. TheStreet cut shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a research note on Monday, March 11th. Truist Financial upped their price objective on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Berenberg Bank boosted their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Finally, Wells Fargo & Company increased their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $133.00.

Read Our Latest Stock Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.